Biocon and Mylan have announced acceptance of the latter’s biologics licence application (BLA) by the US Food and Drug Administration (FDA) for MYL-1401O, a proposed biosimilar trastuzumab.

Mylan’s MYL-1401O is indicated to treat certain HER2-positive breast cancers.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

HER2-positive metastatic breast cancer is an aggressive form of breast cancer that tests positive for the human epidermal growth factor receptor 2 (HER2) that promotes cancer cell growth.

Nearly two million women across the globe are diagnosed with breast cancer every year.

Mylan president Rajiv Malik said: “We believe that our comprehensive package of analytical similarity, non-clinical and clinical data submitted with the BLA will demonstrate similarity of the proposed biosimilar trastuzumab to the reference product.

See Also:

"The product has been co-developed by Mylan and Biocon for the global marketplace and is also under review by the European Medicines Agency (EMA)."

“This is Mylan and Biocon’s first US regulatory submission through the 351(k) pathway and reinforces the strength of our collaboration to increase access to a broad portfolio of high-quality, affordable biosimilars worldwide.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Biocon CEO and joint managing director Dr Arun Chandavarkar added: “This development positions Biocon and Mylan among the first companies to be able to address the critical need of US patients for a high-quality biosimilar to treat certain HER2-positive breast cancers, in the near future.”

The product has been co-developed by Mylan and Biocon for the global marketplace and is also under review by the European Medicines Agency (EMA).

Mylan has exclusive commercialisation rights for this product in the US, Canada, Japan, Australia, New Zealand and the European Union and European Free Trade Association countries. Biocon has co-exclusive rights with Mylan in the remaining parts of the world.